A once-daily weight-loss and type 2 diabetes pill called Foundayo became available in selected UK pharmacies on Monday, Aug. 24, 2026 [1].
The launch provides a critical alternative for patients who cannot tolerate or prefer not to use injectable GLP-1 medications. By moving the treatment from a needle to a tablet, the medication expands access for people managing obesity and metabolic health.
Manufactured by Eli Lilly and Company, the drug is known generically as orforglipron [1]. It is currently available through private prescriptions at selected pharmacies across the United Kingdom [2]. The medication targets the same GLP-1 receptors as popular injectable weight-loss drugs, helping to regulate appetite and blood sugar levels [3].
This release marks the second weight-loss tablet to become readily available in the UK [1]. The United Kingdom was the first European country to approve the pill [4].
While injectable treatments have dominated the weight-loss market, the oral format removes the barrier of needle phobia and the need for cold-chain storage. The tablet is designed for once-daily administration, simplifying the regimen for patients with type 2 diabetes, or those struggling with obesity [3].
Because the drug is available via private prescription, access depends on the patient's ability to pay or their specific insurance coverage. It is not currently listed as a standard NHS prescription for all patients, though it provides a new pathway for those seeking private care [2].
“The United Kingdom was the first European country to approve the pill”
The arrival of Foundayo signifies a shift in the delivery of GLP-1 therapies, moving away from the clinical setting of injections toward home-based pharmacy care. This transition may increase the total addressable market for obesity treatments by capturing patients who avoid needles. Furthermore, the UK's position as the first European nation to approve the drug suggests a regulatory environment that is prioritizing rapid access to metabolic health innovations.
